Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

PHASE3CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

August 31, 2011

Conditions
Seasonal InfluenzaCoughSore ThroatNasal CongestionMyalgiaHeadacheFatigue
Interventions
DRUG

Peramivir

300 mg twice daily

DRUG

Peramivir

600 mg once daily

Trial Locations (110)

Unknown

Dothan

Mobile

Jonesboro

Little Rock

Fountain Valley

Harbor City

La Mesa

Long Beach

Los Angeles

Modesto

Oceanside

Orange

Palo Alto

Sacramento

San Diego

San Francisco

San Jose

Denver

Wheat Ridge

Washington D.C.

Brandon

Fort Lauderdale

Gainsville

Ocoee

Orlando

West Palm Beach

Columbus

Decatur

Honolulu

Idaho Falls

Chicago

Rock Island

Springfield

Indianapolis

South Bend

Topeka

Hazard

Natchitoches

Shreveport

Baltimore

Boston

Detroit

Royal Oak

Troy

Minneapolis

St Louis

Butte

Omaha

Englewood

Hackensack

Neptune City

New Brunswick

Somers Point

Albuquerque

Albany

Brooklyn

Buffalo

Jamaica

New York

The Bronx

Valhalla

Akron

Cleveland

Lima

Toledo

Portland

Philadelphia

Providence

Charleston

Sioux Falls

Houston

San Antonio

Tomball

Salt Lake City

Norfolk

Salem

Bellevue

Seattle

Milwaukee

Brisbane

Cairns

Southport

Clayton

Melbourne

Parkville

Kelowna

Winnipeg

Hamilton

Kingston

Ottawa

Toronto

Chicoutimi

Montreal

Sainte-Foy

Sherbrooke

Trois-Rivières

Saskatoon

Edmonton

Aguascalientes

Guadalajara

Zapopan

Distrito Federal

Monterrey

San Luis Potosí City

Durango

Auckland

Christchurch

Hamilton

Tauranga

San Juan

Sponsors
All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

BioCryst Pharmaceuticals

INDUSTRY